The pathophysiology and treatment of hereditary tyrosinemia type 1
- PMID: 11745044
- DOI: 10.1055/s-2001-19035
The pathophysiology and treatment of hereditary tyrosinemia type 1
Abstract
The topic of this review is hepatorenal tyrosinemia (hereditary tyrosinemia type 1 [HT1], or fumarylacetoacetate hydrolase deficiency; OMIM# 276700). HT1 is the most serious and common of the genetic defects in tyrosine degradation. In addition, this disorder has importance as a model of spontaneous self-correction of liver disease, as a model of liver repopulation by transplanted cells and gene therapy, and as a genetic cause of hepatocarcinoma. However, other forms of hypertyrosinemia exist; hence, the differential diagnosis also will be described briefly. Recent years have seen much progress in our understanding of the molecular basis, the pathophysiology, and especially the treatment of HT1. The current intervention with 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione (NTBC) therapy has improved the outcome of this once devastating disorder. The successful repopulation of the HT1 liver with transplanted cells and positive results in the use of gene therapy in animal models may someday lead to therapy in humans that will obviate the need for life-long dietary and pharmacological therapy.
Similar articles
-
The genetic tyrosinemias.Am J Med Genet C Semin Med Genet. 2006 May 15;142C(2):121-6. doi: 10.1002/ajmg.c.30092. Am J Med Genet C Semin Med Genet. 2006. PMID: 16602095 Review.
-
Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.Biochem Pharmacol. 2006 May 28;71(11):1648-61. doi: 10.1016/j.bcp.2006.02.017. Epub 2006 Apr 3. Biochem Pharmacol. 2006. PMID: 16581029
-
Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.Mol Genet Metab. 2002 Jan;75(1):38-45. doi: 10.1006/mgme.2001.3266. Mol Genet Metab. 2002. PMID: 11825062
-
Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.J Hepatol. 2008 Feb;48(2):308-17. doi: 10.1016/j.jhep.2007.09.014. Epub 2007 Dec 3. J Hepatol. 2008. PMID: 18093685
-
[Hereditary tyrosinemia: an endoplasmic reticulum stress disorder?].Med Sci (Paris). 2003 Oct;19(10):976-80. doi: 10.1051/medsci/20031910976. Med Sci (Paris). 2003. PMID: 14613010 Review. French.
Cited by
-
Tyrosinemia Typel: A case report.Sudan J Paediatr. 2011;11(1):64-7. Sudan J Paediatr. 2011. PMID: 27493308 Free PMC article.
-
Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.J Inherit Metab Dis. 2008 Dec;31 Suppl 2:S223-5. doi: 10.1007/s10545-008-0807-z. Epub 2008 May 20. J Inherit Metab Dis. 2008. PMID: 18500574
-
Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I.Mol Ther Methods Clin Dev. 2021 Apr 9;21:530-547. doi: 10.1016/j.omtm.2021.04.002. eCollection 2021 Jun 11. Mol Ther Methods Clin Dev. 2021. PMID: 33997102 Free PMC article.
-
Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo.Hepatology. 2010 Apr;51(4):1200-8. doi: 10.1002/hep.23481. Hepatology. 2010. PMID: 20162619 Free PMC article.
-
Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease.Stem Cell Res. 2014 Jul;13(1):144-53. doi: 10.1016/j.scr.2014.05.003. Epub 2014 May 14. Stem Cell Res. 2014. PMID: 24879068 Free PMC article.
Publication types
MeSH terms
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
